Turkish Journal of Urology
Original Article

Complications of transrectal ultrasound-guided 12-core prostate biopsy: a single center experience with 2049 patients

1.

Clinic of Urology, Develi Hatice-Muammer Kocatürk State Hospital, Kayseri, Turkey

2.

Department of Urology, Faculty of Medicine, Mersin University, Mersin, Turkey

3.

Department of Urology, Faculty of Medicine, Mersin University, Mersin, Turkey

Turk J Urol 2013; 39: 6-11
DOI: 10.5152/tud.2013.002
Read: 381 Downloads: 144 Published: 25 July 2019

Abstract

Objective: Currently, the performance of a systematic prostate biopsy under transrectal ultrasound (TRUS) guidance is the standard procedure in the diagnosis of prostate cancer. Although TRUS-guided prostate biopsy is considered to be a safe method, it is an invasive procedure that is not free from complications. We prospectively evaluated the morbidity and complication rates for a TRUS-guided 12-core prostate biopsy.

 

Material and methods: The study included 2049 patients undergoing transrectal ultrasound-guided 12-core prostate biopsy. The indications for the prostate biopsy were abnormal digital rectal examination findings and/or an elevated serum total prostate specific antigen (PSA) level (greater than 4 ng/mL). The participants received prophylactic oral ciprofloxacin (500 mg) the night before and the morning of the biopsy, followed by 500 mg orally twice daily for 2 days; patients also received oral alpha blockers for 30 days starting the day before the procedure. A Fleets enema was self-administered the night before the procedure. The complications were assessed both 10 days and 1 month after the biopsy.

 

Results: The mean age, serum total PSA level and prostate volume were 65.4±9.6 years, 18.6±22.4 ng/mL and 51.3±22.4 cc, respectively. From these 2,042 biopsies, 596 cases (29.1%) were diagnosed as prostate cancer. Minor complications, such as hematuria (66.3%), hematospermia (38.8%), rectal bleeding (28.4%), mild to moderate vasovagal episodes (7.7%), and genitourinary tract infection (6.1%) were noted frequently. Major complications were rare and included urosepsis (0.5%), rectal bleeding that required intervention (0.3%), acute urinary retention (0.3%), hematuria that required transfusion (0.05%), Fournier’s gangrene (0.05%), and myocardial infarction (0.05%).

 

Conclusion: TRUS-guided prostate biopsy is safe for diagnosing prostate cancer with few major but frequent minor complications. However, patients should be informed and followed-up with regarding possible complications.

Files
ISSN2149-3235 EISSN 2149-3057